anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
555,547. Moulding artificial dentures &amp;c. in plaster moulds. AMALGAMATED DENTAL CO., Ltd., and WILDING, S. W. May 14, 1942, No. 6571. [Class 87 (ii)] In a process for making artificial dentures or other models or plaster positives by the use of moulds made from plaster of Paris or other plaster composed mainly of calcium sulphate, the mould is coated with a solution in water of a soluble alginate, such as sodium or potassium alginate. The alginate and calcium sulphate interact to form a film of calcium alginate on the mould which prevents the plaster from sticking to the denture and imparts a smooth surface to the denture, which may be made of polymerized methyl methacrylate. The plaster need not be warmed during the modelling process. To prevent the film of calcium alginate from becoming too dry on exposure to the atmosphere and peeling off the plaster, glycerine, ethylene glycol or other hygroscopic substance may be added to the solution.
A telecare system (100) comprises a telecare alarm center (TAC) and a plurality of telecare terminals (TT) for use by respective caretakers (CT) at their respective caretaker residences (CTR). Each telecare terminal (TTi) is configured for transmitting a telecare alarm (1) to the telecare alarm center upon occurrence of an alarm event at the caretaker residence (CTRi). The telecare alarm center is configured, as a result of receiving the telecare alarm from the telecare terminal, to transmit a telecare action request (2) to a caregiving entity (CGC; SG; ES). The telecare alarm center is configured for monitoring the receipt of a telecare action performance confirmation (5) indicating that a caregiving person (CGPj; SG; ES) has appeared at the caretaker residence for the purpose of attending to the alarm event. The telecare system also comprises, for each of the caretaker residences (CTR), an electronic lock device (LDi) for mounting to a door (50i) of the caretaker residence (CTRi). The electronic lock device comprises a transceiver (540) capable of wireless interaction (4a) with a key device (KDk), an electrically controlled lock actuator (512) configured for actuation of a lock mechanism (52) of a lock (54) of the door, and a processing unit (510) coupled to the transceiver and configured to cause the lock actuator to actuate the lock mechanism of the lock in response to wireless interaction with the key device. The processing unit is further configured to cause (4b; 4b&#39;; 4b&#34;) generation of the telecare action performance confirmation (5).
The invention discloses an oxidation/pH dual-response curcumin prodrug and a preparation method thereof, belonging to the field of biomedical high polymer materials. According to the invention, quaternary ammonium salt hydroxyethyl starch is used as a hydrophilic framework, and 3,3&#39; -dithiodipropionic acid is coupled to hydroxyl of the quaternary ammonium salt hydroxyethyl starch through esterification reaction to obtain an intermediate; and then the phenolic hydroxyl of the curcumin and the carboxyl end of the intermediate are subjected to esterification reaction to generate the quaternary ammonium salt hydroxyethyl starch-curcumin prodrug. The curcumin prodrug can be synthesized by a two-step esterification method, and the preparation process is simple. Meanwhile, the prodrug can self-assemble in water to form a stable nano micelle structure, and can improve the solubility of the drug and the enrichment capacity of the drug at tumor positions. The prodrug can rapidly release curcumin under the environment containing active oxygen or weak acidity, and shows good dual responsiveness of active oxygen and pH. The prodrug can effectively inhibit proliferation of tumor cells, and has a certain application prospect in cancer treatment.
A system analyzes and maps the immune system through observational genomics, using multiomic single-cell technologies and machine learning, and uses functional genomics for therapy development including treatment outcome analysis, prediction, and recommendations based on multiomics and longitudinal trajectory analysis. Annotation is performed based on a multiomic classifier and the annotation is validated using RNA/protein pattern recognition per cell subset. Annotating may include automated cell type prediction including dimensionality reduction, feature extraction &amp; automated cell type prediction, multiomic batch effect correction and multiomic based multiplet removal, and may involve separation of sub-cell types. Multiomic data used may comprise gene expression data, CITE seq markers, and TCR/BCR data. Cell type specific matching of clinical signatures with perturbation signatures may include mapping signature against large scale CRISPR perturbations in relevant cell type to identify potential drug targets. Mapping may include signature mapping to clinical covariate.
PURPOSE:To obtain a tooth surface cleaning agent, composed of a suspension prepared by dispersing a powdery cation exchange resin in water, capable of cleaning a smear layer formed on the enamel, etc., due to cutting, etc., by applying to the tooth surface and excellent in adhesion to a dental reparative material without any irritancy. CONSTITUTION:A suspension is obtained by dispersing a powdery cation exchange resin in water. The cation exchange resin is preferably a polystyrene- based gel type strong acidic cation exchange resin, a phenolic strong acidic cation exchange resin, etc. The aforementioned exchange resin is used in a powdery form and the particle diameter thereof is preferably 150 mesh or below. Although the above-mentioned powder is dispersed in water to provide the suspension, the dispersion concentration is preferably &gt;=1%. In clinical use, the aforementioned agent is applied to enamel or dentin surfaces, etc., brought into contact with tooth surfaces for &gt;=10sec, preferably &gt;=30sec and then removed by washing with water.
PROBLEM TO BE SOLVED: To obtain a pollinosis-preventing medicine containing a cation surfactant. SOLUTION: This pollinosis-preventing medicine contains one or more kinds of cationic surfactants having each at least a guanidino group as a cationic group in the molecule and having a surface-activating ability as an active ingredient in an amount of &gt;=0.01wt.% based on the whole amount of the composition. The compound includes hexadecylguanidine hydrochloride and oleylguanidine. The simultaneous use of a basic amino acid or its salt, choline or its derivative improves the effect. The cation surfactant well adsorbs pollens, or further breaks the outer skin of the pollen, acts also on the inner protoplasm to change the protoplasm, and denaturates an antigen itself causing the pollinosis. The action is capable of eliminating the harm of the pollen itself and thereby controlling the crisis of the pollinosis.  The pollinosis-preventing medicine is especially effective for the pollens of Cryptomeria japonica, Ambrosia artemisiifolia, Dactylis glomerata, Solidago serotina, Artemisia princeps, white cedar, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medical image data processing system which enables an efficient use of medical image data in consideration of flexibility of a system structure, the distribution of risks, and the appropriate distribution of processing functions and provides the medical image data in accordance with the purpose of a user while enhancing the operability.  &lt;P&gt;SOLUTION: A medical image data management device (21), a viewer device (31), and an web processing device (41) are connected through a communication network (12). The viewer device sets display protocols in cooperation with the web processing device (41) keeping various kinds of information and provides image data or the like which are suitable for the purpose of use of the user and a service environment such as work of interpretation of photographed images and the reference to the image data at an outpatient clinic, a hospital ward, or a medical office. The viewer device is equipped with features of various measurement of CT values, a cardiothoracic ratio, or the like, MIP/MPR, or the like. The viewer device supports the work of interpretation of photographed images, the reference in a hospital, the disclosure of information, use of data, or the like.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Methods and compositions for performing RNA interference comprising a wide variety of stabilized siRNAs suitable for use in serum-containing media and for in vivo applications, such as therapeutic applications, are provided. These siRNAs permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of one or more modifications including orthoesters, terminal conjugates, modified linkages and 2&#39;modified nucleotides. Uniquely modified siRNAs have been developed that reduces off-target effects incurred in gene-silencing. The modifications include phosphorylation of the first 5&#39; terminal antisense nucleotide; 2&#39; carbon modifications of the first and second or first, second, and third 5&#39; terminal antisense nucleotides; and optionally 2&#39; carbon modifications of the first and second or first, second, and third 5&#39; terminal sense nucleotide. Control and exaequo molecules are also provided. siRNA molecules and related control, trackability and exaequo agents with specific stability modifications were developed.
PURPOSE:To provide a new contraceptive vaccine containing a swine ovum clear zone Zp-4 ingredient as an immunogen and permitting to effectively achieve the contraception. CONSTITUTION:A known swine ovum clear zone Zp-4 ingredient (pzp-4) as a vaccine antigen is prepared into a preparation by a conventional method. For example, the pzp-4 is suspended in a Freund&#39;s perfect adjuvant in a concentration of 10-100mug/ml for its preparation. The vaccine is administered at a dose containing 10-100mug of the pzp-4 as a perfect Freund&#39;s adjuvant at the first time and as an imperfect Freund&#39;s adjuvant at the second time or later several times for each two-four weeks. The vaccine is effectively used for the contraception of man, pets or livestock. A peptide having a specific amino acid sequence and contained in the pzp-4 is useful as an antigen for the contraceptive vaccine.
NEW MATERIAL:A carboxylic acid of formula I (R is H, methyl or hydroxyl; X is alkyl, alkenyl, cycloalkyl, aryl, aralkyl, etc.; Y is aryl, cycloalkyl, heterocyclic, etc.; A is divalent non-cyclic hydrocarbon, etc.; but excludes a case wherein R is H or methyl; X is 1-methylpropyl; the group -A-Y is H or alkyl), an ester thereof and a salt thereof and a lactone compound of formula II. EXAMPLE:1-(2-Methylbutylyl)-3,4-dihydro-6-oxo-4-benzyloxyiminoiso ML-236A lactone. USE:The carboxylic acid of formula I exhibits a serum cholesterol reducing action and is useful as a hyperlipidemia-treating agent or an arterial sclerosis- preventing agent. PREPARATION:A compound of formula III as a starting substance is converted into a compound of formula IV (R&lt;5&gt; is H or a protecting group for the hydroxyl group), from which the protecting group is removed to give the compound of formula II, followed by cleaving the lactone portion thereof to provide the compound of formula I.
1512823 Waving hair L&#39;OREAL 9 June 1975 [10 June 1974] 24715/75 Heading A4V A process for waving hair comprises supporting a lock of hair in a desired configuration, applying super-heated steam to the hair for a period of up to 60 seconds and cooling the hair to ambient temperature, for example by means of a stream of air at ambient temperature, before releasing it. Fig. 1 shows a device in which super-heated steam produced in a vaporizing element 6 into which liquid is pumped from a reservoir 9, is injected through a perforated injector needle 7 into the centre of a curler or wave-setting roller. The vaporizing element comprises a metal body with electrical resistance heaters and a chamber (18), Fig. 3 (not shown) filled with metal shot. In a modification, Figs. 4 to 6 (not shown), the injector needle 7 is surrounded by a protective sleeve (30) which is mounted to slide telescopically against the action of a return spring (31) and which has an enlarged head (34) which is pushed back to expose the steam discharge orifices (8) when the device is inserted into a curler. In each case a fan provides a circulation of cold air through the apparatus to protect the scalp and to cool the hair; in Fig. 1 the air is discharged around the needle while in Fig. 6 (not shown) a slot (29) distributes a flat curtain of cold air. In Fig. 7 (not shown) the super-heated steam escapes through a porous mass (7a) instead of through a needle. In order to protect the scalp, the curlers are advantageously provided with means for spacing a lock of hair wound on the curler from the scalp. Figs. 10 to 16 (not shown) depict suitable such curlers. Fig. 8 shows a curling tongs in which a fan 4 passes a stream of air inside the body of the apparatus and steam is produced in a vaporizing element 45 consisting of a porous body, a resistance heater 21 and a vaporizing chamber 46. The liquid to be vaporized is contained under pressure in a cartridge 44 and when a pushbutton 43 is pressed, a valve 53 opens so that gas under pressure expels liquid into the chamber 46 where it is converted to superheated steam. Fig. 18 (not shown) depicts another type of curling tongs. Other embodiments of apparatus for injecting super-heated steam into curlers are illustrated in Figs. 17, 19 and 20 (not shown). In these embodiments, the liquid reservoir is made of a flexible material and can be disposable.
The present invention relates to a medicine for treatment of skin ulcer. The medicine comprises, by weight, 5-15 parts of selaginella tamariscina, 3-8 parts of borneol, 10-20 of rheum officinale; 5-15 parts of litharge; 5-15 parts of catechu; 10-20 parts of crude fossil fragments; 10-20 parts of Chinese angelica; 3-8 parts of cinnabar; 5-15 parts of frankincense; 3-8 parts of dragon&#39;s blood; 4-12 parts of lithospermum; 6-14 parts of Chinese magnoliavine; and 10-16 parts of calamine. Traditional Chinese medicines of the invention are formulated by clinical combination for several times, The medicine has effects of invigorating blood circulation and dispelling slough, relieving pain and promoting regeneration, engendering flesh, astringing sore and solidifying skin, nourishing blood, moistening skin and dispelling turgescence. The medicine is based on systemic treatment, treats both principal and secondary aspect of disease after being used. Proved by hundreds of clinical experiments, the medicine has obvious effects for severe and lingering ulcer, complex wound (such as cutting, stamping contusion, open fracture, and the like), bedsore, lower limb ulcer, and the like. The effective rate achieves 92%. The medicine has high cure rate.
PURPOSE:To obtain the titled compound useful as an emulsifying agent industrially and advantageously, by reacting a carboxylic acid with a carbodiimide in a nonpolar solvent to form an acid anhydride and reacting the acid anhydride with pulverized L-alpha-glycerophosphorylcholine in the presence of a base. CONSTITUTION:An acid (e.g. myristic acid) shown by the formula RCOOH (R is 9-21C hydrocarbon) is reacted with N,N&#39;-dicyclohexylcarbodiimide in a nonpolar solvent to form an acid anhydride shown by the formula (RCO)2O. Then the acid anhydride is reacted with pulverized L-alpha-glycerophosphorylcholine in a nonpolar solvent in the presence of a basic catalyst (e.g. N,N&#39;-dimethyl-4- aminopyridine) to give the aimed lecithin shown by the formula. The diameter of the fine particles of L-alpha-glycerophosphorylcholine is preferably &lt;=500mu.
The present invention relates to a device that provides a treatment protocol for a disease, wherein the device includes a communication unit and a processor. The processor provides a treatment protocol user interface (UI) for the user&#39;s disease to a user terminal. When answer information to the question about the disease is input through the UI, the treatment protocol for the user is set based on the answer information. Treatment tasks for treatment dates for each treatment stage included in the set treatment protocol are displayed. Performance information on the treatment task is input through the UI. When the treatment task is completed based on the performance information, treatment process log data is input through the UI. When the treatment task is completed for each treatment step, the end of the treatment step is decided by determining the number of input treatment process log data. When the number of treatment process log data for each treatment step is a preset number, the treatment protocol may be terminated. The present invention has the effect of maximizing the effectiveness of treatment carried out in hospitals over a certain period of time.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new contact lens capable of safely providing a contact lens whose expiration date is preliminarily determined to a user without imposing any excess load on the user or a oculist and to provide its diagnosing system.  &lt;P&gt;SOLUTION: A user 18 is made to share a periodical membership fee, and the contact lens is provided through a preliminarily selected member store 14 to the user 18. That is, it is possible to provide new contact lens for exchange to the member user 18 who continues to pay the periodical membership fee without requiring any special procedure when the user 18 visits the member store 14. Also, the user 18 is able to receive periodical medical examination at the member store 14 at receiving the provision of the contact lens. Then, a providing main body 10 of the contact lens manages various information including the personal information of the user, and constructs a database 24.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
PROBLEM TO BE SOLVED: To obtain a new compound having excellent antiulcer activity and useful for treating digestive ulcer. SOLUTION: This new compound is shown by formula I [R&lt;1&gt; is a (substituted) (hetero)aryl; R&lt;2&gt; is H, an alkoxycarbonyl, substituted aminocarbonyl, cyano or the like; R&lt;3&gt; and R&lt;4&gt; are each H, a substituted alkyl, aryl, amino or the like], e.g. 4-amino-2-oxo-1-phenyl-1,2-dihydroquinoline-3-carboxylic ethyl ester. The compound of formula I is obtained by reaction of a compound of formula II with ethyl malonate of the formula CH2 (COOEt)2 pref. in the presence of a base at 25-100 deg.C for 24-72 h. The amounts of the ethyl malonate and the base to be used are 1-5 equivalents, based on the compound of formula II, respectively. The reaction is carried out under an anhydrous condition in a solventless state or in a solvent such as anhydrous ethanol. The base to be used is e.g. sodium ethoxide.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a prenyl derivative compound having an inhibitory effect against NO production, and an anti-inflammatory agent containing the same.  &lt;P&gt;SOLUTION: The new compound is the prenyl derivative compound of formula (I) (wherein Het is a heterocyclic group of formula (II), (III) or (IV)). The compound can be prepared through a known process using as a starting material a compound obtained by the extraction of the root of Ferula fukanensis K M shen with an organic solvent (e.g. methanol, chloroform or ethyl acetate). The compound has an inhibitory effect against NO production and is useful as an anti-inflammatory agent or an antiallergic agent.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
FIELD: medicine.SUBSTANCE: bio material is taken using a vaginal or urethral probe by scraping the vagina. The number of genomic equivalents of microorganism and their fraction in the total bacterial mass are determined using the &#34;Femoflor-16&#34; reagent kit by real-time PCR. If the proportion of Lactobacillus spp. is more than 80%, normocenosis, characterized by the dominance of normoflora is diagnosed. If the proportion of Lactobacillus spp. is less than 80%, dysbiosis is diagnosed. At vaginal atrophy against a background of normocoenosis hormonal therapy is appointed. At a vaginal atrophy against a background of dysbiosis hormonal therapy and lactic culture containing preparations are appointed.EFFECT: invention provides development of individual approaches to vaginal atrophy treatment in postmenopausal women, taking into account the state of the vaginal biocenosis.5 tbl, 3 ex
FIELD: medicine. ^ SUBSTANCE: invention can be used for making a probiotic preparation exhibiting an antagonistic effect on opportunistic and pathogenic bacteria and yeast fungi, as well as expressed anti-enteroviral activity. &#39;Pashkov&#39; Bacillus pumilus bacteria strain is recovered from the environment in the Department of Microbiology, Virology and Immunology of the I.M.Sechenov Moscow Medical Academy, and deposited in the L.A.Tarasevich State Standartisation and Control under No. 286. ^ EFFECT: strain shows a wide spectrum of antagonistic activity, low adhesive activity, high anti-enteroviral activity of strain secretion products. ^ 8 tbl
Duchenne muscular dystrophy (DMD) is a progressive muscle disease that is caused by severe defects in the dystrophin gene and results in the patient&#39;s death by the third decade. The present invention utilizes the Double Mutant mice (DM) as an appropriate human model for DMD as these mice are deficient for both dystrophin and utrophin (mdxl+, utrn -/-), die at 3 months of age and suffer from severe muscle weakness, pronounced growth retardation, kyphosis, weight loss, slack posture, and immobility. Expression from a transgene of novel human retinal dystrophin Dp260 was shown to prevent premature death and reduce the severe muscular dystrophy phenotype to a mild clinical myopathy. Electromyography, histology, radiography, magnetic resonance imaging, and behavior studies concluded that DM transgenic mice grew normally, had normal spinal curvature and mobility, and had reduced muscle pathology. EMG and histologic data from transgenic DM mice showed decreased abnormalities to levels typical of mild myopathy, while the DM mice exhibited severe abnormalities commonly seen in human dystrophinopathies. The transgenic DM mice also has measurable movement levels comparable to those of untreated mdx mice and controls.
FIELD: veterinary and microbiological methods. SUBSTANCE: drug for prophylactics and treatment of gastro-intestinal conditions in calves is prepared as follows. Brewer&#39;s yeast is repeatedly centrifuged to give pasty precipitate, which is flooded with 0.4% solution of sodium hydroxide in amount corresponding to 10 l of alkali solution per 2-2.5 kg paste. Resulting mixture is stirred and kept 1 day at room temperature, after which centrifuged at rotation speed 4000 rpm for 10-12 min. To separated supernatant, 5% acetic acid solution (0.6 l per 1 l of supernatant) is added, after which rapidly stirred until total precipitation of yeast nucleoprotein is attained. Suspension is allowed to stand 1-1.5 h and centrifugation is repeated. After supernatant is removed, dense grayish white dense paste of yeast nucleoprotein is obtained containing 1.8-2.0% of nucleic acids. EFFECT: increased resistance of organism.
An edible chew pill jacket receives a pill/tablet or capsule that is to be administered to a pet, animal or human. The edible chew pill jacket includes a flexible top wall, side walls and bottom wall configured to form a chamber appointed to receive a pill. A flexible longitudinal slit is integrated within the top wall for providing access to the chamber for insertion of the pill within the edible chew pill jacket. The edible chew pill jacket is formulated with at least one flavoring to provide a tasty treat appointed to mask the pill&#39;s taste. The chew pill jacket substantially encapsulates the pill/tablet appointed to be orally ingested. The chew pill jacket may include medicament therein, nutrients, vitamins, or may simply be provided as a tasty treat to mask the taste of the pill.